Endovasc Ltd. Inc. to Initiate Clinical Trials for Critical Limb Salvage At UT-Houston Medical School.MONTGOMERY, Texas--(BW HealthWire)--July 21, 1998--Endovasc Ltd. Inc. (NASD NASD See: National Association of Securities Dealers NASD See National Association of Securities Dealers (NASD). OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. :ENDV) today announced that it will begin its first human studies of its liposomal prostaglandin E-1 (LLPGE-1) for salvage of limbs in patients whose only alternative is limp amputation amputation (ăm'pyətā`shən), removal of all or part of a limb or other body part. Although amputation has been practiced for centuries, the development of sophisticated techniques for treatment and prevention of infection has greatly . The study will be under the direction of Dr. Richard K. Smalling, M.D., Ph.D., its principal investigator. The study will commence in September or as soon as the company receives clearance from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. of its review of animal data. Company CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dr. David P. Summers, stated, "PGE-1 in liposomal form has had some spectacular results in animals. It is now time to move to the human phase. Our investigation will determine whether or not this hormone can produce an extension of life in a limb that would otherwise be lost to amputation. We are confident that we can provide an additional reprieve for the limb. The question we will ask is: How long?" Endovasc Ltd. Inc. is a biopharmaceutical company using liposomal drug delivery for products that have already shown safety and efficacy in the generic form. The company products and processes are covered by patents and trade secrets for competing in a $2 billion market. CONTACT: RMJ & Associates, Houston 281/596-9000 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion